Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Waters ACQUITY UPC2 System Wins Green Innovation Prize

Published: Monday, June 17, 2013
Last Updated: Monday, June 17, 2013
Bookmark and Share
System hailed for replacing organic solvents with compressed carbon dioxide as primary mobile phase constituent for greener laboratory separations.

On June 6, Waters Corporation’s ACQUITY UPC2™ System was awarded a Green Innovation Award at Forum LABO and BIOTECH 2013, France’s premier laboratory science trade show and exhibition.

The ACQUITY UPC2 System, substitutes mainly carbon dioxide for organic solvents for chromatographic separations and excels at applications as varied as fat soluble vitamins, lipids, organic light emitting diodes (OLEDs), and chiral compound analysis.

Laboratory-dependent organizations often consume large amounts of organic solvents that are expensive to purchase and can be twice as expensive to dispose of.

Many of these organizations have set aggressive sustainability goals for themselves and are investigating the potential of Waters® UPC2 Technology to help meet them and, in turn, save hundreds of thousands of dollars over time.

Normal phase LC is one solvent-hungry technique that the ACQUITY® UPC2 system seeks to replace.

For these reasons, interest in the technology is especially intense among firms with large laboratory operations. In a videotaped interview, Daniel Zimmerli, a senior scientist in the Pharmaceuticals Division at J. Hoffman-LaRoche (Basel, Switzerland) talked about the potential of UPC2 Technology to cut solvent usage and, in his estimation, replace normal phase LC in “3 to 5 years”.

Technological innovation, and the growth of corporation sustainability initiatives, have played a significant role in the renewed interest in SFC and convergence chromatography.

A recent article on UPC2 in the June 1 issue of Genetic Engineering and Biotechnology News reports that the carbon footprint for manufacturing acetonitrile is substantial.

With acetonitrile, a common LC solvent, costing between $300 - $400/four-liter bottle - and more than twice that to dispose of - organizations are taking a second look at their consumption of organic solvents in the laboratory.

CO2 on the other hand is extracted from the atmosphere and vented to it after use. As the article states, CO2 is the “greenest HPLC solvent, hands down.”

UPC2 Technology is based on the principles of UltraPerformance Convergence Chromatography™ which employs compressed CO2 as the primary mobile phase constituent.

The instrument is based on the robust, reliable low-dispersion design of the Waters ACQUITY UPLC® platform perfected for use with sub-two-micron particle technology.

As an orthogonal technique to LC and GC, ACQUITY UPC2 System is finding many applications within the pharmaceutical and life sciences, chemical materials, environmental and food and beverage industries.

The technique is suitable for a diverse range of compounds including most organic-soluble compounds, most salts of organic acids and bases, small lipophilic peptides and non-polar solutes.

It is ideal for structurally similar compounds including chiral entities, diastereomers, enantiomers, positional isomers and structural analogs.

Essentially any compound soluble in an organic solvent is a candidate for convergence chromatography. The technique is also compatible with a most popular detection modes including mass spectrometry.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More Than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

It is All About the Product, Right?
Technology Networks met with Waters Corporation at its head office in Milford, MA to better understand the factors they use to drive business success.
Monday, January 11, 2016
R&D 100 Award Goes to Waters ionKey/MS System
Novel approach is enhancing the sensitivity of bioanalytical, biomarker validation, pharmacokinetic and food research LC/MS analyses.
Thursday, November 26, 2015
SIMM Honored by Waters Centers of Innovation Program
Research Center for traditional Chinese medicine modernization recognized for advancing quality control authentication and profiling methods.
Wednesday, October 28, 2015
Waters’ Centers of Innovation Program Honors Ohio State University Laboratory
Wysocki-led facility recognized for proteomics, disease research and mass spectrometry excellence.
Wednesday, September 23, 2015
Waters Corporation Announces Christopher J. O'Connell as CEO
Chris joins Waters® from Medtronic plc.
Thursday, July 02, 2015
Waters Centers of Innovation Program Honors CSU Laboratory
Proteomics and metabolomics facility recognized for innovation in biological mass spectrometry.
Wednesday, October 29, 2014
Waters Q3 Revenues up 8 Percent
Company reports third quarter sales of $493 million, an increase of 8% versus sales of $457 million in the third quarter of 2013.
Tuesday, October 21, 2014
Waters, Chinese Pharmacopeia Commission Establish Joint Open Laboratory
Located in the laboratory building of Beijing Zhendong Guangming Drug Research Institute, the new facility is over 400m2.
Thursday, July 10, 2014
New Solutions to Old Challenges
Waters Corporation introduces a new NuGenesis Lab Management System (LMS) that integrates sample management functions and business operations across the enterprise. Technology Networks' Editor Helen Gillespie interviewed Waters' Garrett Mullen for details.
Tuesday, July 01, 2014
Waters, Prosolia Exclusive Agreement for DESI Technology for Clinical MS Applications
Prosolia DESI Technology now available on SYNAPT G2 Si and Xevo G2-XS QTof mass spectrometers.
Monday, June 16, 2014
Waters, Omics LLC Partner to Advance Petroleum Sample Analysis
Collaboration Combines the Value of Ion Mobility Mass Spectrometry (IM-MS) and Accurate Mass Information with Petroleomics Data Processing.
Monday, June 16, 2014
Waters ACQUITY UPLC TQD System Receives Chinese FDA Approval
Chinese FDA approves ACQUITY UPLC TQD system for routine diagnostic applications and neonatal metabolites diseases screening.
Thursday, June 05, 2014
Waters ACQUITY QDa Detector Takes Pittcon Editors' Award
Product receives Editors' Silver award for the most innovative product introduced at Pittcon 2014.
Monday, March 10, 2014
Waters Report 8% Revenue Increase
Fourth quarter 2013 sales were $565 million, an increase of 8% compared to sales of $522 million in the fourth quarter of 2012.
Tuesday, January 28, 2014
Waters Teams With Biochemical Society on Proteomics Training Day and Symposium
The consecutive events will take place on March 24 - 27, 2014 in Chester, England.
Wednesday, November 27, 2013
Scientific News
The Rise of 3D Cell Culture and in vitro Model Systems for Drug Discovery and Toxicology
An overview of the current technology and the challenges and benefits over 2D cell culture models plus some of the latest advances relating to human health research.
World’s Largest Coral Gene Database
‘Genetic toolkit’ will help shed light on which species survive climate change.
A Boost for Regenerative Medicine
Growing tissues and organs in the lab for transplantation into patients could become easier after scientists discovered an effective way to produce three-dimensional networks of blood vessels, vital for tissue survival yet a current stumbling block in regenerative medicine.
Breast Cancer Drug Hope
A drug for breast cancer that is more effective than existing medicines may be a step closer thanks to new research.
Untangling Disease-Related Protein Misfolding
Work advances understanding of genetic forms of thrombosis, emphysema, cirrhosis of the liver, neurodegenerative diseases and inflammation, among others.
Early Genetic Changes in Premalignant Colorectal Tissue Identified
Findings point to drivers of early cancer development, targets for cancer prevention therapies.
Harnessing Nature’s Vast Array of Venoms for Drug Discovery
Scripps scientists have developed a method for rapidly identifying venoms.
Nanoparticles Target, Transform Fat Tissue
Nanoparticles designed to target white fat and convert it to calorie-burning brown fat slowed weight gain in obese mice without affecting food intake. This proof-of-concept work could lead to new therapies to treat obesity.
New Cancer Fighters Emerge From Lab
Rice University lab simplifies total synthesis of anti-cancer agent.
Scientists Find Evidence That Cancer Can Arise Changes
Researchers at Rockefeller University have found a mutation that affects the proteins that package DNA without changing the DNA itself can cause a rare form of cancer.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!